Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,609.50
Bid: 1,609.00
Ask: 1,610.00
Change: -0.50 (-0.03%)
Spread: 1.00 (0.062%)
Open: 1,611.50
High: 1,614.00
Low: 1,602.00
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Sep 2017 16:07

RNS Number : 5501Q
GlaxoSmithKline PLC
12 September 2017
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHELLFFDKFBBBE
Date   Source Headline
23rd Aug 20197:00 amRNSGSK - positive results from pivotal DREAMM-2 study
22nd Aug 20197:00 amRNSViiV results positive for every 2 month injection
21st Aug 20198:00 amRNSGSK submits regulatory file in Japan: Daprodustat
12th Aug 20193:45 pmRNSDirector/PDMR Shareholding
1st Aug 20193:30 pmRNSEU approval for Nucala self-administration
1st Aug 20192:10 pmRNSTotal Voting Rights
1st Aug 20197:00 amRNSGSK completes transaction with Pfizer for New JV
30th Jul 20193:35 pmRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSViiV submits cabotegravir to EMA for HIV injection
24th Jul 20196:01 pmRNSDirector/PDMR Shareholding
24th Jul 20194:01 pmRNSViiV 2DR TANGO switch study positive at 48 weeks
24th Jul 20194:00 pmRNSViiV GEMINI studies show high efficacy at 96 weeks
24th Jul 201912:07 pmRNSSecond Price Monitoring Extn
24th Jul 201912:02 pmRNSPrice Monitoring Extension
24th Jul 201912:00 pmRNS2nd Quarter Results
24th Jul 201910:00 amRNSNon-Executive Chairman
22nd Jul 20195:00 pmRNSViiV presents 96-week data from phase III study
15th Jul 20196:19 pmRNSDirector/PDMR Shareholding
15th Jul 20196:18 pmRNSDirector/PDMR Shareholding
15th Jul 20196:16 pmRNSDirector/PDMR Shareholding
15th Jul 201911:42 amRNSDirector/PDMR Shareholding
15th Jul 20197:00 amRNSpositive results in Phase 3 PRIMA study of ZEJULA
12th Jul 20194:35 pmRNSDirector/PDMR Shareholding
12th Jul 20193:55 pmRNSDirector/PDMR Shareholding
10th Jul 20193:48 pmRNSDirector/PDMR Shareholding
10th Jul 20197:00 amRNSViiV switch study shows 2DR as effective as 3DR
1st Jul 201912:08 pmRNSTotal Voting Rights
12th Jun 20195:10 pmRNSDirector/PDMR Shareholding
7th Jun 20197:00 amRNSFDA approval for Nucala self-administration
4th Jun 20198:00 amRNSCHMP positive on GSK's Nucala self-administration
3rd Jun 20192:31 pmRNSTotal Voting Rights
24th May 201910:54 amRNSDirector/PDMR Shareholding
20th May 20191:44 pmRNSDirector/PDMR Shareholding
13th May 20195:44 pmRNSBlock listing Interim Review
13th May 20194:19 pmRNSDirector/PDMR Shareholding
8th May 20196:23 pmRNSResult of AGM & GM
2nd May 20195:07 pmRNSTrelegy Ellipta asthma study met primary endpoint
1st May 20193:11 pmRNSDirector/PDMR Shareholding
1st May 20192:32 pmRNSTotal Voting Rights
1st May 201912:00 pmRNS1st Quarter Results
29th Apr 201912:00 pmRNSViiV submits NDA for HIV monthly 2 drug injectable
26th Apr 20194:16 pmRNSViiV receives CHMP Positive Opinion for Dovato
16th Apr 20195:36 pmRNSDirector/PDMR Shareholding
16th Apr 20195:35 pmRNSDirector/PDMR Shareholding
16th Apr 20195:23 pmRNSDirector/PDMR Shareholding
16th Apr 20195:14 pmRNSDirector/PDMR Shareholding
15th Apr 20192:45 pmRNSDirector/PDMR Shareholding
12th Apr 20194:47 pmRNSDirector/PDMR Shareholding
12th Apr 20194:33 pmRNSDirector/PDMR Shareholding
11th Apr 20195:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.